In era of immunotherapy: the value of trastuzumab beyond progression in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer
Background: For patients with human epidermal growth factor receptor-2 (HER2)-positive advanced or metastatic gastric cancer who have progressed on first-line trastuzumab therapy, the clinical value of the continuous use of trastuzumab beyond progression (TBP) is controversial. Objectives: The prese...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| 格式: | 文件 |
| 语言: | English |
| 出版: |
SAGE Publishing
2024-04-01
|
| 丛编: | Therapeutic Advances in Gastroenterology |
| 在线阅读: | https://doi.org/10.1177/17562848241245455 |
| _version_ | 1827287107877470208 |
|---|---|
| author | Hui Wang Caiyun Nie Weifeng Xu Jing Li He Gou Huifang Lv Beibei Chen Jianzheng Wang Yingjun Liu Yunduan He Jing Zhao Xiaobing Chen |
| author_facet | Hui Wang Caiyun Nie Weifeng Xu Jing Li He Gou Huifang Lv Beibei Chen Jianzheng Wang Yingjun Liu Yunduan He Jing Zhao Xiaobing Chen |
| author_sort | Hui Wang |
| collection | DOAJ |
| description | Background: For patients with human epidermal growth factor receptor-2 (HER2)-positive advanced or metastatic gastric cancer who have progressed on first-line trastuzumab therapy, the clinical value of the continuous use of trastuzumab beyond progression (TBP) is controversial. Objectives: The present study was conducted to evaluate the efficacy and explore new treatment strategies of TBP for patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer in the era of cancer immunotherapy. Design: Retrospective analysis. Methods: Patients with HER2-positive advanced or metastatic gastric cancer who have failed first-line treatment based on trastuzumab-targeted therapy from June 2019 to December 2020 were retrospectively analyzed. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety. Survival curves of patients were estimated by the Kaplan–Meier method and compared using the log-rank test. Results: In all, 30 patients received TBP with chemotherapy, immunotherapy, or anti-angiogenic therapy, and the other 26 patients received treatment of physician’s choice without trastuzumab. The median PFS in the TBP and non-TBP population was 6.0 [95% confidence interval (CI) = 3.8–8.2] and 3.5 (95% CI = 2.2–4.8) months, respectively ( p = 0.038), and the median OS was 12.3 (95% CI = 10.4–14.2) and 9.0 (95% CI = 6.6–11.4) months ( p = 0.008). The patients who received TBP treatment had more favorable PFS and OS than the non-TBP population. In the TBP group, patients who received trastuzumab plus chemotherapy and immunotherapy had higher ORR (40.0% versus 16.7%), DCR (90.0% versus 50.0%), and showed a significant improvement in PFS (7.0 versus 1.9 m) compared to TBP with chemotherapy alone. Subgroup analysis suggested that patients with male, HER2 positive with immunohistochemistry score 3+ and PFS of first-line treatment less than 6 months had a greater benefit from TBP. The incidence of Grade 3–4 adverse events in the TBP and non-TBP groups was 43.3% and 38.5%. Conclusion: The continuous use of TBP improves PFS and OS in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer with well-tolerated toxicity. In the era of immunotherapy, TBP combined with chemotherapy and immunotherapy may further enhance the clinical benefit and provide a new treatment strategy. Trial registration: This study is a retrospective study, which does not require clinical registration. |
| first_indexed | 2024-04-24T10:51:31Z |
| format | Article |
| id | doaj.art-eb461969120c41c78b75358b50e2f1a6 |
| institution | Directory Open Access Journal |
| issn | 1756-2848 |
| language | English |
| last_indexed | 2024-04-24T10:51:31Z |
| publishDate | 2024-04-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Gastroenterology |
| spelling | doaj.art-eb461969120c41c78b75358b50e2f1a62024-04-12T12:04:21ZengSAGE PublishingTherapeutic Advances in Gastroenterology1756-28482024-04-011710.1177/17562848241245455In era of immunotherapy: the value of trastuzumab beyond progression in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancerHui WangCaiyun NieWeifeng XuJing LiHe GouHuifang LvBeibei ChenJianzheng WangYingjun LiuYunduan HeJing ZhaoXiaobing ChenBackground: For patients with human epidermal growth factor receptor-2 (HER2)-positive advanced or metastatic gastric cancer who have progressed on first-line trastuzumab therapy, the clinical value of the continuous use of trastuzumab beyond progression (TBP) is controversial. Objectives: The present study was conducted to evaluate the efficacy and explore new treatment strategies of TBP for patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer in the era of cancer immunotherapy. Design: Retrospective analysis. Methods: Patients with HER2-positive advanced or metastatic gastric cancer who have failed first-line treatment based on trastuzumab-targeted therapy from June 2019 to December 2020 were retrospectively analyzed. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety. Survival curves of patients were estimated by the Kaplan–Meier method and compared using the log-rank test. Results: In all, 30 patients received TBP with chemotherapy, immunotherapy, or anti-angiogenic therapy, and the other 26 patients received treatment of physician’s choice without trastuzumab. The median PFS in the TBP and non-TBP population was 6.0 [95% confidence interval (CI) = 3.8–8.2] and 3.5 (95% CI = 2.2–4.8) months, respectively ( p = 0.038), and the median OS was 12.3 (95% CI = 10.4–14.2) and 9.0 (95% CI = 6.6–11.4) months ( p = 0.008). The patients who received TBP treatment had more favorable PFS and OS than the non-TBP population. In the TBP group, patients who received trastuzumab plus chemotherapy and immunotherapy had higher ORR (40.0% versus 16.7%), DCR (90.0% versus 50.0%), and showed a significant improvement in PFS (7.0 versus 1.9 m) compared to TBP with chemotherapy alone. Subgroup analysis suggested that patients with male, HER2 positive with immunohistochemistry score 3+ and PFS of first-line treatment less than 6 months had a greater benefit from TBP. The incidence of Grade 3–4 adverse events in the TBP and non-TBP groups was 43.3% and 38.5%. Conclusion: The continuous use of TBP improves PFS and OS in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer with well-tolerated toxicity. In the era of immunotherapy, TBP combined with chemotherapy and immunotherapy may further enhance the clinical benefit and provide a new treatment strategy. Trial registration: This study is a retrospective study, which does not require clinical registration.https://doi.org/10.1177/17562848241245455 |
| spellingShingle | Hui Wang Caiyun Nie Weifeng Xu Jing Li He Gou Huifang Lv Beibei Chen Jianzheng Wang Yingjun Liu Yunduan He Jing Zhao Xiaobing Chen In era of immunotherapy: the value of trastuzumab beyond progression in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer Therapeutic Advances in Gastroenterology |
| title | In era of immunotherapy: the value of trastuzumab beyond progression in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer |
| title_full | In era of immunotherapy: the value of trastuzumab beyond progression in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer |
| title_fullStr | In era of immunotherapy: the value of trastuzumab beyond progression in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer |
| title_full_unstemmed | In era of immunotherapy: the value of trastuzumab beyond progression in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer |
| title_short | In era of immunotherapy: the value of trastuzumab beyond progression in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer |
| title_sort | in era of immunotherapy the value of trastuzumab beyond progression in patients with trastuzumab resistant her2 positive advanced or metastatic gastric cancer |
| url | https://doi.org/10.1177/17562848241245455 |
| work_keys_str_mv | AT huiwang ineraofimmunotherapythevalueoftrastuzumabbeyondprogressioninpatientswithtrastuzumabresistanther2positiveadvancedormetastaticgastriccancer AT caiyunnie ineraofimmunotherapythevalueoftrastuzumabbeyondprogressioninpatientswithtrastuzumabresistanther2positiveadvancedormetastaticgastriccancer AT weifengxu ineraofimmunotherapythevalueoftrastuzumabbeyondprogressioninpatientswithtrastuzumabresistanther2positiveadvancedormetastaticgastriccancer AT jingli ineraofimmunotherapythevalueoftrastuzumabbeyondprogressioninpatientswithtrastuzumabresistanther2positiveadvancedormetastaticgastriccancer AT hegou ineraofimmunotherapythevalueoftrastuzumabbeyondprogressioninpatientswithtrastuzumabresistanther2positiveadvancedormetastaticgastriccancer AT huifanglv ineraofimmunotherapythevalueoftrastuzumabbeyondprogressioninpatientswithtrastuzumabresistanther2positiveadvancedormetastaticgastriccancer AT beibeichen ineraofimmunotherapythevalueoftrastuzumabbeyondprogressioninpatientswithtrastuzumabresistanther2positiveadvancedormetastaticgastriccancer AT jianzhengwang ineraofimmunotherapythevalueoftrastuzumabbeyondprogressioninpatientswithtrastuzumabresistanther2positiveadvancedormetastaticgastriccancer AT yingjunliu ineraofimmunotherapythevalueoftrastuzumabbeyondprogressioninpatientswithtrastuzumabresistanther2positiveadvancedormetastaticgastriccancer AT yunduanhe ineraofimmunotherapythevalueoftrastuzumabbeyondprogressioninpatientswithtrastuzumabresistanther2positiveadvancedormetastaticgastriccancer AT jingzhao ineraofimmunotherapythevalueoftrastuzumabbeyondprogressioninpatientswithtrastuzumabresistanther2positiveadvancedormetastaticgastriccancer AT xiaobingchen ineraofimmunotherapythevalueoftrastuzumabbeyondprogressioninpatientswithtrastuzumabresistanther2positiveadvancedormetastaticgastriccancer |